Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 33 entries
Sorted by: Best Match Show Resources per page
Pivotal Role for Cxcr2 in Regulating Tumor-Associated Neutrophil in Breast Cancer.

Cancers

Timaxian C, Vogel CFA, Orcel C, Vetter D, Durochat C, Chinal C, NGuyen P, Aknin ML, Mercier-Nomé F, Davy M, Raymond-Letron I, Van TN, Diermeier SD, Godefroy A, Gary-Bobo M, Molina F, Balabanian K, Lazennec G.
PMID: 34070438
Cancers (Basel). 2021 May 25;13(11). doi: 10.3390/cancers13112584.

Chemokines present in the tumor microenvironment are essential for the control of tumor progression. We show here that several ligands of the chemokine receptor Cxcr2 were up-regulated in the PyMT (polyoma middle T oncogene) model of breast cancer. Interestingly,...

Cite
Timaxian C, Vogel CFA, Orcel C, et al. Pivotal Role for Cxcr2 in Regulating Tumor-Associated Neutrophil in Breast Cancer. Cancers (Basel). 2021;13(11)doi: 10.3390/cancers13112584.
Timaxian, C., Vogel, C. F. A., Orcel, C., Vetter, D., Durochat, C., Chinal, C., NGuyen, P., Aknin, M. L., Mercier-Nomé, F., Davy, M., Raymond-Letron, I., Van, T. N., Diermeier, S. D., Godefroy, A., Gary-Bobo, M., Molina, F., Balabanian, K., & Lazennec, G. (2021). Pivotal Role for Cxcr2 in Regulating Tumor-Associated Neutrophil in Breast Cancer. Cancers, 13(11), . https://doi.org/10.3390/cancers13112584
Timaxian, Colin, et al. "Pivotal Role for Cxcr2 in Regulating Tumor-Associated Neutrophil in Breast Cancer." Cancers vol. 13,11 (2021). doi: https://doi.org/10.3390/cancers13112584
Timaxian C, Vogel CFA, Orcel C, Vetter D, Durochat C, Chinal C, NGuyen P, Aknin ML, Mercier-Nomé F, Davy M, Raymond-Letron I, Van TN, Diermeier SD, Godefroy A, Gary-Bobo M, Molina F, Balabanian K, Lazennec G. Pivotal Role for Cxcr2 in Regulating Tumor-Associated Neutrophil in Breast Cancer. Cancers (Basel). 2021 May 25;13(11). doi: 10.3390/cancers13112584. PMID: 34070438; PMCID: PMC8197482.
Copy Download .nbib Format: NLM
Noncoding RNAs: biology and applications-a Keystone Symposia report.

Annals of the New York Academy of Sciences

Cable J, Heard E, Hirose T, Prasanth KV, Chen LL, Henninger JE, Quinodoz SA, Spector DL, Diermeier SD, Porman AM, Kumar D, Feinberg MW, Shen X, Unfried JP, Johnson R, Chen CK, Wilusz JE, Lempradl A, McGeary SE, Wahba L, Pyle AM, Hargrove AE, Simon MD, Marcia M, Przanowska RK, Chang HY, Jaffrey SR, Contreras LM, Chen Q, Shi J, Mendell JT, He L, Song E, Rinn JL, Lalwani MK, Kalem MC, Chuong EB, Maquat LE, Liu X.
PMID: 34791665
Ann N Y Acad Sci. 2021 Dec;1506(1):118-141. doi: 10.1111/nyas.14713. Epub 2021 Nov 17.

The human transcriptome contains many types of noncoding RNAs, which rival the number of protein-coding species. From long noncoding RNAs (lncRNAs) that are over 200 nucleotides long to piwi-interacting RNAs (piRNAs) of only 20 nucleotides, noncoding RNAs play important...

Cite
Cable J, Heard E, Hirose T, et al. Noncoding RNAs: biology and applications-a Keystone Symposia report. Ann N Y Acad Sci. 2021;1506(1):118-141doi: 10.1111/nyas.14713.
Cable, J., Heard, E., Hirose, T., Prasanth, K. V., Chen, L. L., Henninger, J. E., Quinodoz, S. A., Spector, D. L., Diermeier, S. D., Porman, A. M., Kumar, D., Feinberg, M. W., Shen, X., Unfried, J. P., Johnson, R., Chen, C. K., Wilusz, J. E., Lempradl, A., McGeary, S. E., Wahba, L., Pyle, A. M., Hargrove, A. E., Simon, M. D., Marcia, M., Przanowska, R. K., Chang, H. Y., Jaffrey, S. R., Contreras, L. M., Chen, Q., Shi, J., Mendell, J. T., He, L., Song, E., Rinn, J. L., Lalwani, M. K., Kalem, M. C., Chuong, E. B., Maquat, L. E., & Liu, X. (2021). Noncoding RNAs: biology and applications-a Keystone Symposia report. Annals of the New York Academy of Sciences, 1506(1), 118-141. https://doi.org/10.1111/nyas.14713
Cable, Jennifer, et al. "Noncoding RNAs: biology and applications-a Keystone Symposia report." Annals of the New York Academy of Sciences vol. 1506,1 (2021): 118-141. doi: https://doi.org/10.1111/nyas.14713
Cable J, Heard E, Hirose T, Prasanth KV, Chen LL, Henninger JE, Quinodoz SA, Spector DL, Diermeier SD, Porman AM, Kumar D, Feinberg MW, Shen X, Unfried JP, Johnson R, Chen CK, Wilusz JE, Lempradl A, McGeary SE, Wahba L, Pyle AM, Hargrove AE, Simon MD, Marcia M, Przanowska RK, Chang HY, Jaffrey SR, Contreras LM, Chen Q, Shi J, Mendell JT, He L, Song E, Rinn JL, Lalwani MK, Kalem MC, Chuong EB, Maquat LE, Liu X. Noncoding RNAs: biology and applications-a Keystone Symposia report. Ann N Y Acad Sci. 2021 Dec;1506(1):118-141. doi: 10.1111/nyas.14713. Epub 2021 Nov 17. PMID: 34791665.
Copy Download .nbib Format: NLM
[Posterior meniscus root tears].

Der Orthopade

Balke M, Metzlaff S, Faber S, Niethammer T, Roessler PP, Henkelmann R, Diermeier T, Kurme A, Winkler PW, Colcuc S, Zimmermann GR, Petersen W.
PMID: 34767042
Orthopade. 2021 Dec;50(12):1039-1050. doi: 10.1007/s00132-021-04192-8.

Meniscus root tears are radial tears in the region of the posterior insertion zones. Medial root injuries usually occur in individuals > 50 years of age without adequate trauma and are associated with obesity and varus deformities. The root...

Cite
Balke M, Metzlaff S, Faber S, et al. Posteriore Wurzelverletzungen der Menisken. [Posterior meniscus root tears]. Orthopade. 2021;50(12):1039-1050doi: 10.1007/s00132-021-04192-8.
Balke, M., Metzlaff, S., Faber, S., Niethammer, T., Roessler, P. P., Henkelmann, R., Diermeier, T., Kurme, A., Winkler, P. W., Colcuc, S., Zimmermann, G. R., & Petersen, W. (2021). Posteriore Wurzelverletzungen der Menisken. [Posterior meniscus root tears]. Der Orthopade, 50(12), 1039-1050. https://doi.org/10.1007/s00132-021-04192-8
Balke, Maurice, et al. "Posteriore Wurzelverletzungen der Menisken." [Posterior meniscus root tears]. Der Orthopade vol. 50,12 (2021): 1039-1050. doi: https://doi.org/10.1007/s00132-021-04192-8
Balke M, Metzlaff S, Faber S, Niethammer T, Roessler PP, Henkelmann R, Diermeier T, Kurme A, Winkler PW, Colcuc S, Zimmermann GR, Petersen W. Posteriore Wurzelverletzungen der Menisken. [Posterior meniscus root tears]. Orthopade. 2021 Dec;50(12):1039-1050. doi: 10.1007/s00132-021-04192-8. German. PMID: 34767042.
Copy Download .nbib Format: NLM
Single-Cell RNA-Seq Reveals Heterogeneous lncRNA Expression in Xenografted Triple-Negative Breast Cancer Cells.

Biology

Pinkney HR, Black MA, Diermeier SD.
PMID: 34681087
Biology (Basel). 2021 Sep 30;10(10). doi: 10.3390/biology10100987.

Breast cancer is the most commonly diagnosed cancer in the world, with triple-negative breast cancer (TNBC) making up 12% of these diagnoses. TNBC tumours are highly heterogeneous in both inter-tumour and intra-tumour gene expression profiles, where they form subclonal...

Cite
Pinkney HR, Black MA, Diermeier SD. Single-Cell RNA-Seq Reveals Heterogeneous lncRNA Expression in Xenografted Triple-Negative Breast Cancer Cells. Biology (Basel). 2021;10(10)doi: 10.3390/biology10100987.
Pinkney, H. R., Black, M. A., & Diermeier, S. D. (2021). Single-Cell RNA-Seq Reveals Heterogeneous lncRNA Expression in Xenografted Triple-Negative Breast Cancer Cells. Biology, 10(10), . https://doi.org/10.3390/biology10100987
Pinkney, Holly R, et al. "Single-Cell RNA-Seq Reveals Heterogeneous lncRNA Expression in Xenografted Triple-Negative Breast Cancer Cells." Biology vol. 10,10 (2021). doi: https://doi.org/10.3390/biology10100987
Pinkney HR, Black MA, Diermeier SD. Single-Cell RNA-Seq Reveals Heterogeneous lncRNA Expression in Xenografted Triple-Negative Breast Cancer Cells. Biology (Basel). 2021 Sep 30;10(10). doi: 10.3390/biology10100987. PMID: 34681087; PMCID: PMC8533545.
Copy Download .nbib Format: NLM
Functional Screening Techniques to Identify Long Non-Coding RNAs as Therapeutic Targets in Cancer.

Cancers

Lucere KM, O'Malley MMR, Diermeier SD.
PMID: 33317042
Cancers (Basel). 2020 Dec 09;12(12). doi: 10.3390/cancers12123695.

Recent technological advancements such as CRISPR/Cas-based systems enable multiplexed, high-throughput screening for new therapeutic targets in cancer. While numerous functional screens have been performed on protein-coding genes to date, long non-coding RNAs (lncRNAs) represent an emerging class of potential...

Cite
Lucere KM, O'Malley MMR, Diermeier SD. Functional Screening Techniques to Identify Long Non-Coding RNAs as Therapeutic Targets in Cancer. Cancers (Basel). 2020;12(12)doi: 10.3390/cancers12123695.
Lucere, K. M., O'Malley, M. M. R., & Diermeier, S. D. (2020). Functional Screening Techniques to Identify Long Non-Coding RNAs as Therapeutic Targets in Cancer. Cancers, 12(12), . https://doi.org/10.3390/cancers12123695
Lucere, Kathleen M, et al. "Functional Screening Techniques to Identify Long Non-Coding RNAs as Therapeutic Targets in Cancer." Cancers vol. 12,12 (2020). doi: https://doi.org/10.3390/cancers12123695
Lucere KM, O'Malley MMR, Diermeier SD. Functional Screening Techniques to Identify Long Non-Coding RNAs as Therapeutic Targets in Cancer. Cancers (Basel). 2020 Dec 09;12(12). doi: 10.3390/cancers12123695. PMID: 33317042; PMCID: PMC7763270.
Copy Download .nbib Format: NLM
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer.

Biomedicines

Rana Z, Diermeier S, Hanif M, Rosengren RJ.
PMID: 32019149
Biomedicines. 2020 Jan 30;8(2). doi: 10.3390/biomedicines8020022.

Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to standard treatments, such as docetaxel and enzalutamide. Histone deacetylase (HDAC) inhibitors showed promising results in hematological malignancies, but they failed in solid tumors such as...

Cite
Rana Z, Diermeier S, Hanif M, et al. Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer. Biomedicines. 2020;8(2)doi: 10.3390/biomedicines8020022.
Rana, Z., Diermeier, S., Hanif, M., & Rosengren, R. J. (2020). Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer. Biomedicines, 8(2), . https://doi.org/10.3390/biomedicines8020022
Rana, Zohaib, et al. "Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer." Biomedicines vol. 8,2 (2020). doi: https://doi.org/10.3390/biomedicines8020022
Rana Z, Diermeier S, Hanif M, Rosengren RJ. Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer. Biomedicines. 2020 Jan 30;8(2). doi: 10.3390/biomedicines8020022. PMID: 32019149; PMCID: PMC7168248.
Copy Download .nbib Format: NLM
Noncoding RNAs: biology and applications-a Keystone Symposia report.

Annals of the New York Academy of Sciences

Cable J, Heard E, Hirose T, Prasanth KV, Chen LL, Henninger JE, Quinodoz SA, Spector DL, Diermeier SD, Porman AM, Kumar D, Feinberg MW, Shen X, Unfried JP, Johnson R, Chen CK, Wilusz JE, Lempradl A, McGeary SE, Wahba L, Pyle AM, Hargrove AE, Simon MD, Marcia M, Przanowska RK, Chang HY, Jaffrey SR, Contreras LM, Chen Q, Shi J, Mendell JT, He L, Song E, Rinn JL, Lalwani MK, Kalem MC, Chuong EB, Maquat LE, Liu X.
PMID: 34791665
Ann N Y Acad Sci. 2021 Dec;1506(1):118-141. doi: 10.1111/nyas.14713. Epub 2021 Nov 17.

The human transcriptome contains many types of noncoding RNAs, which rival the number of protein-coding species. From long noncoding RNAs (lncRNAs) that are over 200 nucleotides long to piwi-interacting RNAs (piRNAs) of only 20 nucleotides, noncoding RNAs play important...

Cite
Cable J, Heard E, Hirose T, et al. Noncoding RNAs: biology and applications-a Keystone Symposia report. Ann N Y Acad Sci. 2021;1506(1):118-141doi: 10.1111/nyas.14713.
Cable, J., Heard, E., Hirose, T., Prasanth, K. V., Chen, L. L., Henninger, J. E., Quinodoz, S. A., Spector, D. L., Diermeier, S. D., Porman, A. M., Kumar, D., Feinberg, M. W., Shen, X., Unfried, J. P., Johnson, R., Chen, C. K., Wilusz, J. E., Lempradl, A., McGeary, S. E., Wahba, L., Pyle, A. M., Hargrove, A. E., Simon, M. D., Marcia, M., Przanowska, R. K., Chang, H. Y., Jaffrey, S. R., Contreras, L. M., Chen, Q., Shi, J., Mendell, J. T., He, L., Song, E., Rinn, J. L., Lalwani, M. K., Kalem, M. C., Chuong, E. B., Maquat, L. E., & Liu, X. (2021). Noncoding RNAs: biology and applications-a Keystone Symposia report. Annals of the New York Academy of Sciences, 1506(1), 118-141. https://doi.org/10.1111/nyas.14713
Cable, Jennifer, et al. "Noncoding RNAs: biology and applications-a Keystone Symposia report." Annals of the New York Academy of Sciences vol. 1506,1 (2021): 118-141. doi: https://doi.org/10.1111/nyas.14713
Cable J, Heard E, Hirose T, Prasanth KV, Chen LL, Henninger JE, Quinodoz SA, Spector DL, Diermeier SD, Porman AM, Kumar D, Feinberg MW, Shen X, Unfried JP, Johnson R, Chen CK, Wilusz JE, Lempradl A, McGeary SE, Wahba L, Pyle AM, Hargrove AE, Simon MD, Marcia M, Przanowska RK, Chang HY, Jaffrey SR, Contreras LM, Chen Q, Shi J, Mendell JT, He L, Song E, Rinn JL, Lalwani MK, Kalem MC, Chuong EB, Maquat LE, Liu X. Noncoding RNAs: biology and applications-a Keystone Symposia report. Ann N Y Acad Sci. 2021 Dec;1506(1):118-141. doi: 10.1111/nyas.14713. Epub 2021 Nov 17. PMID: 34791665.
Copy Download .nbib Format: NLM
Inactivation and regeneration of peroxidase in heat-treated plant tissues.

Biochemische Zeitschrift

HERRLINGER F, KIERMEIER F.
PMID: 18887940
Biochem Z. 1948;318(4):413-24.

No abstract available.

Cite
HERRLINGER F, KIERMEIER F. Inaktivierung und Regeneration der Peroxydase in wärmebehandelten Pflanzengeweben. Inactivation and regeneration of peroxidase in heat-treated plant tissues. Biochem Z. 1948;318(4):413-24
HERRLINGER, F., & KIERMEIER, F. (1948). Inaktivierung und Regeneration der Peroxydase in wärmebehandelten Pflanzengeweben. Inactivation and regeneration of peroxidase in heat-treated plant tissues. Biochemische Zeitschrift, 318(4), 413-24.
HERRLINGER, F, and KIERMEIER, F. "Inaktivierung und Regeneration der Peroxydase in wärmebehandelten Pflanzengeweben." Inactivation and regeneration of peroxidase in heat-treated plant tissues. Biochemische Zeitschrift vol. 318,4 (1948): 413-24.
HERRLINGER F, KIERMEIER F. Inaktivierung und Regeneration der Peroxydase in wärmebehandelten Pflanzengeweben. Inactivation and regeneration of peroxidase in heat-treated plant tissues. Biochem Z. 1948;318(4):413-24. German. PMID: 18887940.
Copy Download .nbib Format: NLM
Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids.

Bio-protocol

Diermeier SD, Spector DL.
PMID: 28932764
Bio Protoc. 2017 Aug 20;7(16). doi: 10.21769/BioProtoc.2511.

Primary mammary tumor organoids grown in 3D are an excellent system to study tumor biology. They resemble the organization and physiology of native epithelia more closely than cancer cell lines grown in 2D, and additionally model interactions with the...

Cite
Diermeier SD, Spector DL. Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids. Bio Protoc. 2017;7(16)doi: 10.21769/BioProtoc.2511.
Diermeier, S. D., & Spector, D. L. (2017). Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids. Bio-protocol, 7(16), . https://doi.org/10.21769/BioProtoc.2511
Diermeier, Sarah D, and Spector, David L. "Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids." Bio-protocol vol. 7,16 (2017). doi: https://doi.org/10.21769/BioProtoc.2511
Diermeier SD, Spector DL. Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids. Bio Protoc. 2017 Aug 20;7(16). doi: 10.21769/BioProtoc.2511. PMID: 28932764; PMCID: PMC5602589.
Copy Download .nbib Format: NLM
Micro-bias and macro-performance.

The European physical journal. B

Seaver SM, Moreira AA, Sales-Pardo M, Malmgren RD, Diermeier D, Amaral LA.
PMID: 24860255
Eur Phys J B. 2009 Feb 01;67(3):369-375. doi: 10.1140/epjb/e2008-00406-4.

We use agent-based modeling to investigate the effect of conservatism and partisanship on the efficiency with which large populations solve the density classification task - a paradigmatic problem for information aggregation and consensus building. We find that conservative agents...

Cite
Seaver SM, Moreira AA, Sales-Pardo M, et al. Micro-bias and macro-performance. Eur Phys J B. 2009;67(3):369-375doi: 10.1140/epjb/e2008-00406-4.
Seaver, S. M., Moreira, A. A., Sales-Pardo, M., Malmgren, R. D., Diermeier, D., & Amaral, L. A. (2009). Micro-bias and macro-performance. The European physical journal. B, 67(3), 369-375. https://doi.org/10.1140/epjb/e2008-00406-4
Seaver, S M D, et al. "Micro-bias and macro-performance." The European physical journal. B vol. 67,3 (2009): 369-375. doi: https://doi.org/10.1140/epjb/e2008-00406-4
Seaver SM, Moreira AA, Sales-Pardo M, Malmgren RD, Diermeier D, Amaral LA. Micro-bias and macro-performance. Eur Phys J B. 2009 Feb 01;67(3):369-375. doi: 10.1140/epjb/e2008-00406-4. PMID: 24860255; PMCID: PMC4029510.
Copy Download .nbib Format: NLM
Treatment After Anterior Cruciate Ligament Injury: Panther Symposium ACL Treatment Consensus Group.

Orthopaedic journal of sports medicine

Diermeier T, Rothrauff BB, Engebretsen L, Lynch AD, Ayeni OR, Paterno MV, Xerogeanes JW, Fu FH, Karlsson J, Musahl V, Brown CH, Chmielewski TL, Clatworthy M, Villa SD, Ernlund L, Fink C, Getgood A, Hewett TE, Ishibashi Y, Johnson DL, Macalena JA, Marx RG, Menetrey J, Meredith SJ, Onishi K, Rauer T, Rothrauff BB, Schmitt LC, Seil R, Senorski EH, Siebold R, Snyder-Mackler L, Spalding T, Svantesson E, Wilk KE.
PMID: 32637434
Orthop J Sports Med. 2020 Jun 24;8(6):2325967120931097. doi: 10.1177/2325967120931097. eCollection 2020 Jun.

Treatment strategies for anterior cruciate ligament (ACL) injuries continue to evolve. Evidence supporting best-practice guidelines for the management of ACL injury is to a large extent based on studies with low-level evidence. An international consensus group of experts was...

Cite
Diermeier T, Rothrauff BB, Engebretsen L, et al. Treatment After Anterior Cruciate Ligament Injury: Panther Symposium ACL Treatment Consensus Group. Orthop J Sports Med. 2020;8(6):2325967120931097doi: 10.1177/2325967120931097.
Diermeier, T., Rothrauff, B. B., Engebretsen, L., Lynch, A. D., Ayeni, O. R., Paterno, M. V., Xerogeanes, J. W., Fu, F. H., Karlsson, J., Musahl, V., Brown, C. H., Chmielewski, T. L., Clatworthy, M., Villa, S. D., Ernlund, L., Fink, C., Getgood, A., Hewett, T. E., Ishibashi, Y., Johnson, D. L., Macalena, J. A., Marx, R. G., Menetrey, J., Meredith, S. J., Onishi, K., Rauer, T., Rothrauff, B. B., Schmitt, L. C., Seil, R., Senorski, E. H., Siebold, R., Snyder-Mackler, L., Spalding, T., Svantesson, E., & Wilk, K. E. (2020). Treatment After Anterior Cruciate Ligament Injury: Panther Symposium ACL Treatment Consensus Group. Orthopaedic journal of sports medicine, 8(6), 2325967120931097. https://doi.org/10.1177/2325967120931097
Diermeier, Theresa, et al. "Treatment After Anterior Cruciate Ligament Injury: Panther Symposium ACL Treatment Consensus Group." Orthopaedic journal of sports medicine vol. 8,6 (2020): 2325967120931097. doi: https://doi.org/10.1177/2325967120931097
Diermeier T, Rothrauff BB, Engebretsen L, Lynch AD, Ayeni OR, Paterno MV, Xerogeanes JW, Fu FH, Karlsson J, Musahl V, Brown CH, Chmielewski TL, Clatworthy M, Villa SD, Ernlund L, Fink C, Getgood A, Hewett TE, Ishibashi Y, Johnson DL, Macalena JA, Marx RG, Menetrey J, Meredith SJ, Onishi K, Rauer T, Rothrauff BB, Schmitt LC, Seil R, Senorski EH, Siebold R, Snyder-Mackler L, Spalding T, Svantesson E, Wilk KE. Treatment After Anterior Cruciate Ligament Injury: Panther Symposium ACL Treatment Consensus Group. Orthop J Sports Med. 2020 Jun 24;8(6):2325967120931097. doi: 10.1177/2325967120931097. eCollection 2020 Jun. PMID: 32637434; PMCID: PMC7315684.
Copy Download .nbib Format: NLM
Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer.

Pharmaceuticals (Basel, Switzerland)

Rana Z, Diermeier S, Walsh FP, Hanif M, Hartinger CG, Rosengren RJ.
PMID: 34681244
Pharmaceuticals (Basel). 2021 Oct 04;14(10). doi: 10.3390/ph14101020.

Metastatic castration-resistant prostate cancer (CRPC) has a five-year survival rate of 28%. As histone deacetylases (HDACs) are overexpressed in CRPC, the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) was trialled in CRPC patients but found to be toxic and inefficacious....

Cite
Rana Z, Diermeier S, Walsh FP, et al. Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals (Basel). 2021;14(10)doi: 10.3390/ph14101020.
Rana, Z., Diermeier, S., Walsh, F. P., Hanif, M., Hartinger, C. G., & Rosengren, R. J. (2021). Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals (Basel, Switzerland), 14(10), . https://doi.org/10.3390/ph14101020
Rana, Zohaib, et al. "Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer." Pharmaceuticals (Basel, Switzerland) vol. 14,10 (2021). doi: https://doi.org/10.3390/ph14101020
Rana Z, Diermeier S, Walsh FP, Hanif M, Hartinger CG, Rosengren RJ. Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals (Basel). 2021 Oct 04;14(10). doi: 10.3390/ph14101020. PMID: 34681244; PMCID: PMC8540814.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 33 entries